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It  has  become  increasingly  clear  that  immunoglobulin  molecules  expressed  on 
precursors of antibody-secreting cells act not only as membrane receptors for antigen 
but also as sites for the regulatory action of specific antibodies (1, 2) and T  lymphocytes 
(3-6). One especially striking example of this Ig-specific regulatory control is provided 
by the chronic suppression of IgG2a antibodies of the b  allelic type (IgGza  b) 1, 2 in (SJL 
X BALB/c)F1 hybrids maternally or neonatally treated with anti-allotype antibodies 
(7).  Because the regulation  of IgG2a  b may provide a  particularly  powerful system to 
study  the  normal  control  of Ig class  and  ailotype  expression,  it  is  of considerable 
importance to delineate the genetic regulation and idiotypic character of anti-allotype 
antibodies  in  general,  and  of anti-IgGza  b antibodies  in  particular.  Lieberman  and 
Humphrey  (8,  9)  have  previously  demonstrated  that  antibody  responses  to  the  a 
allelic  forms of IgA (IgA  a)  and  IgGza (IgG2,  ")  are  regulated  by major histocompati- 
bility complex  (MHC)  immune  response  (It)  genes.  The responses  to IgA  ~ determi- 
nants  depend on a  gene  (or genes)  in the I-A subregion of the MHC  with mice of a, 
/g p,  r,  and  s  haplotypes  being  responders.  Responses  to  IgGz~  a  determinants  are 
regulated  by an/-B-encoded Ir gene with responder alleles being found in mice of b, 
p, r, s, and v haplotypes. 
In this communication, we report data that indicate that responses to the b  al|elic 
form of IgG2, are  also  regulated  by MHC-encoded  /r  genes.  Furthermore,  we  find 
that all responder strains produce anti-IgG2,  b antibodies that share common idiotypes 
(cross-reactive  idiotypes  [IdX]),  no  matter  what  allelic  forms  of the  Ig heavy  (H)- 
chain-constant region (Igh-C)  genes they possess. It appears that  the variable regions 
of these anti-allotype antibodies are encoded by a  family of highly conserved genes. 
Materials  and Methods 
Animals.  8-wk-old mice were used  in these experiments.  Their MHC and lgh-C types are 
presented in Table I. 
* Recipient of fellowship 1F32 AI 05568-02 from the Public Health Service, National Institute of  Allergy 
and Infectious Diseases, National Institutes of Health. 
IgG~ of the b allotype is designated Ig-IB in the Herzenberg nomenclature. Similarly, IgG2a  a is Ig-la, 
IgA  a is Ig-2a, IgG2b  a is Ig-3a, and IgGl  a is Ig-4a. 
2  Abbreviations used in this paper: H, heavy; HA, hemagglutination;  HI, inhibition of hemagglutination; 
IdX, cross-reactive idiotype(s); IgA  a, the a allelic type of IgA; IgGza  a, the a allelic type of IgG2,; IgG2~  h, the 
b allelic form of IgG~; Igh-C, Ig H-chain-constant region; Igl-V, Ig light-chain-variable region; Igh-V, Ig 
H-chain-variable region; KLH, keyhole limpet hemocyanin; L, light; MHC,  major histocompatibility 
complex; Ova, ovalbumin: RIA, radioimmunoassay; SRBC, sheep red blood cells. 
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Mydoma Proteins.  CBPCI01  (IgG~  b)  myeloma protein was obtained from ascitic fluid of 
C.B20 mice that bore the CBPC101  myeloma tumor. It was purified on a protein A-Sepharose 
4B column (Pharmacia Fine Chemical Co., Div. of Pharmacia, Inc., Piscataway, N. J.). UPC10 
and  LPC1  (IgG2aa), MOPC195  (IgG2ba), MOPC31C  (IgGl"), and  UPC61  (IgA  a)  myeloma 
proteins were obtained from Dr. M. Potter (National Cancer Institute, National Institutes of 
Health, Bethesda, Md.). 
Products  of hybridomas No.  10-3.6,  Ig(lb)5.7.1,  Ig(lb)3.1, Ig(lb)2.9, and  Ig(lb)4.7 were 
obtained from Dr. V. Oi and Dr. L. Herzenberg (Stanford University, Stanford, Calif.) and 
S1G.1E and S1A.1A from Dr. M. Bosma (Institute for Cancer Research, Fox Chase, Pa.). 
Immunization of Mice. 
PREPARATION  OF  ANTI-lcG~.  h  ALLOTYPE  ANTIBODY  IN  VARIOUS  STRAINS  OF  MICE.  Anti-allotype 
antibodies were prepared by immunization of mice with 75 pg of CBPC101  myeloma protein 
emulsified in complete Freund's adjuvant (CFA). This was followed 5 d later by a similar dose 
of myeloma protein in incomplete Freund's adjuvant and then by one to six weekly injections 
of 75 #g of myeloma protein in saline. 
PREPARATION  OF ANTI-IDIOTYPE (Id) SERUM.  BALB/c anti-IgGza  b allotype antibodies from an 
individual mouse and pooled C.AL20, P/J, and DBA/2 anti-IgG2a  b allotype antibodies were 
purified by affinity chromatography on a  column of CBPC101-Sepharose 4B according to a 
previously described technique (10).  These purified anti-allotype antibodies were coupled to 
keyhole limpet hemocyanin (KLH) at a  1:1 ratio as previously described (10).  BAB. 14, CXBI, 
and B.C8 mice were immunized with the anti-allotype-KLH conjugate according to the same 
schedule as that used to raise anti-allotype antibodies. These antisera were made specific for Id 
by adsorption with BALB/c, BALB.B, P/J, C.AL20, or DBA/2 immunoglobulins as described 
by Lieberman and Humphrey (8). 
Coating of Sheep Erythrocytes (SRBC).  SRBC  were  coated  with  myeloma  proteins,  with 
purified BALB/c, C.AL20, P/J, and DBA/2 anti-CBPC 101  antibodies and with C57BL/6 Ig 
by the chromic chloride method using a concentration of 1 mg/ml of the appropriate protein 
(6). 
Determination of  Hemagglutinin (HA) Titers.  HA titers of antibodies specific for IgG2a  b allotypic 
determinants were measured in microtiter plates using SRBC that were coated with CBPC101 
or C57BL/6 Ig. The titer of anti-class or anti-allotype antibodies specific for Igh-C determinants 
of the a  allotypic form was determined using UPC10,  MOPC195,  MOPC31C,  and UPC61- 
coated SRBC. In each case, the titer recorded is 1/log2 of the highest dilution of antisera that 
caused agglutination. 
Determination of Serum IdX  Titer.  A  hemagglutination-inhibition  (HI)  method  described 
previouslyb(2  ) was used to test sera for Id. In these experiments, specifically purified BALB/c 
anti-IgGh  antibodies were coupled to SRBC. The capacity of various sera to inhibit aggluti- 
nation  of these cells by BAB.14, CXBI,  or B.C8  anti-(BALB/c anti-IgG2a  b)  antibodies was 
determined.  The  titer  reported  is  1/log2  of the  highest  dilution  that  caused  inhibition of 
hemagglutination. 
Radioimmunoassay.  Purified BALB/c, C.AL20, P/J, and DBA/2 anti-IgG2a  b antibodies were 
tritiated according to a  technique described by Wilder et  al.  (11).  The specific activity was 
~0.05 pCi//~g protein. 
The ability of 3H-BALB/e, -C.AL20, -P/J, and -DBA/2 anti-IgG~  b antibodies to be bound 
by BAB.14, CXBI, or B.C8 anti-Id antisera was determined as follows: Microtiter plates were 
coated with various dilutions of anti-Id antisera by overnight  incubation followed by three 
washings with saline. The plates were then incubated with 50% fetal calf serum (FCS) in saline. 
After three washings with saline, they were incubated with 3H-anti-IgG2a  b for 3 h. The plates 
were then exhaustively washed and dried. Radioactivity on plates was measured in a  liquid 
scintillation spectrometer (Beckman  Instruments,  Inc.,  Fullerton, Calif.). To  determine the 
capacity of various anti-IgGh  b antisera to inhibit  the binding of 3H-anti-IgG2~  b by anti-Id 
antibodies,  plates  that  were  already  coated  with  BAB.14,  CXBI,  or  B.C8  antisera  were 
incubated for at least 3 h with various dilutions of the inhibitory sera prior to the addition of 
aH-antibodies. 
Isoelectric Focusing.  Anti-IgG2~  b antisera were analyzed by isoelectric focusing according to a 
previously described technique  (12).  Gels were  overlaid with  a  12SI-labeled  Fc  fragment  of 1336  REGULATION OF  ANTI-ALLOTYPE RESPONSE 
CBPC101  myeloma protein,  kindly donated  by  Dr.  M.  Stanislavsky,  Centre  National  de 
Recherche Scientifique, Villejuif, France. 
Results 
Genetic Control of Production of Anti-Allotype (IgG2a b) Antibody.  Various strains of mice 
were injected with CBPC 101 myeloma protein, and the titer of anti-allotype antibody 
was determined by HA assay.  In those cases in which sera agglutinated  CBPC101- 
and C57BL/6-Ig-coated SRBC at a similar dilution, we concluded that anti-allotype 
antibody  was  present,  whereas  for  those  cases  in  which  the  sera  agglutinated 
CBPC101-coated  SRBC  but  not  C57BL/6-Ig-coated  SRBC,  we  concluded  that 
antibodies specific for the Id of the CBPC101  myeloma protein  (anti-Id CBPCI01) 
were present. 
Mice of the d (i.e., BALB/c, DBA/2, and C.AL20), r (i.e., RIII), p  (i.e., P/J), q (i.e., 
DBA/1J),  and  s  (i.e.,  SJA)  haplotypes  made  very  strong  anti-allotype  antibody 
responses as  a  result  of immunization  with  CBPC101.  Among mice of the b type, 
BALB.B., B.C8, CXBJ, and CXBG made strong responses; however, only one of five 
129/SV  mice  made  anti-allotype  antibody,  whereas  two  mice  made  only  anti-Id 
CBPC101  antibody. Mice of the k (i.e.,  CBA/J, CBA/N, BALB.K, C3H/HeN, CE/ 
J, c58/j, and AKR), m (i.e., AKR.M), a  (i.e., A/He), a I (i.e.,  AL/N), u (i.e.,  PL/J), 
and z (i.e.,  NZW/J)  haplotypes made no, or only a  very poor, response (Table I). It 
should be noted that the HA titer of CBA/N serum probably does not represent anti- 
allotype antibody because this serum agglutinates UPC-10  (IgG2aa)-coated SRBC to 
the same extent as it agglutinates CBPC101-coated SRBC. 
The  importance  of MHC  genes  in  this  response  is  shown  by  the  fact  that  an 
excellent correlation between MHC  type and anti-allotype response exists.  Further- 
more, among a series of congenic strains, including BALB/c (H-2a), BALB.B (H-2b), 
and  BALB.K (H-2k), the  H-2  d and  H-2  b strains  respond, although  the  H-2  k strain 
does not. Although these results indicate that the critical genes are within the MHC, 
they do not map such genes more precisely. We have been unable, thus far, to carry 
out intra-MHC mapping largely because strains which themselves possess IgG2a  b (e.g., 
C57BL/10) do not make anti-allotype antibody to CBPC101;  thus,  the B10 recom- 
binant series cannot be employed for mapping. 
Characterization  of  Anti-Id  Antibodies  Against  BALB/c  Anti-Allotype  (IgG2a b) 
Antibodies.  BAB.14 and CXBI mice were immunized with affinity chromatography- 
purified anti-CBPC101  antibodies coupled to KLH. The anti-CBPCl01  antibodies 
used  for immunization originated from a  single  BALB/c mouse.  Four BAB.14 and 
three  CXBI  mice  developed high-titered  antibodies  which  agglutinated  SRBC  to 
which BALB/c anti-CBPC 101 antibodies had been coupled. These sera were pooled 
and found to have little or no activity against  SRBC coupled with UPC10  (IgGza~), 
MOPC195 (IgG2ba), MOPC31C  (IgGl~),  and UPC61  (IgAa).  The agglutination titer 
of the  pool  of BAB. 14  antisera  for  SRBC  coupled  with  BALB/C  anti-CBPC101 
antibody was 2.6 ×  10  ~, whereas that of CXBI pooled serum was 1.3 ×  10  ~ (Table II). 
Furthermore, BAB. 14 and CXBI normal sera, BAB. 14 anti-(BALB/c anti-ovalbumin 
[Ova]) serum, CBPC101  (10 mg/ml), and C57BL/6 Ig (2 mg/ml) caused little or no 
agglutination  of  SRBC  that  were  coated  with  purified  BALB/c  anti-CBPC101 
antibody.  Thus,  the  ability  of  anti-(BALB/c  anti-CBPC101)  antibody  to  cause 
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MHC  Igh-C  Strain*  type  type 
HA titer (log2) on SRBC coated 
with 
CBPCI01  C57BL/6  UPCIO 
Ig  (IgG~,,  ~) 
BALB/c AnN  d  a 
C.AL20  d  o 
DBA/2J  d  c 
BALB.B  b  a 
B.C8  b  a 
CXBJ  b  a 
CXBG  b  a 
129/SV*  b  a 
BALB.K  k  a 
C58/J  k  a 
CBA/J  k  j 
CBA/N  k  j 
C3H/HeN  k  j 
AKR/N  k  d 
CE/J  k  f 
A/He  a  e 
AL/N  a 1  o 
AKR.M  m  d 
RIII  r  g 
P/J  p  h 
NZW/J  z  n 
PL/J  u  j 
DBA/IJ  q  c 
SJA  s  a 
>12  >12  0 
11  >12  1.5 
>12  >12  5.5 
11  10  0 
11.5  8.5  0 
>12  7  2 
10  >12  0 
>12  >12  0 
0  0  0 
4  2  0 
0  0  0 
7  4  8 
4  1.5  1 
0  0  0 
2.3  1  2 
1.5  0.5  2 
0  0  0 
0  0  0 
>12  >12  2 
>12  >12  0 
1.5  1  0 
3.1  5.4  2.8 
9  9  0 
>12  >12  0 
* Three to five mice were tested for each strain. 
:[: Only one out of five mice made anti-allotype antibody. 
binding of anti-CBPC  101 to IgG2a  b in the agglutinating  sera. Rather,  it must represent 
the  activity  of  anti-Id  antibody  in  the  CXBI  and  BAB.14  anti-(BALB/c  anti- 
CBPC 101)  antisera. 
Anti-Id  antibodies  against  anti-IgG2a  b  allotype  antibodies  were  also  obtained  in 
B.C8  mice  by  immunization  with  BALB/c  anti-CBPC101  antibodies.  B.C8  mice 
possess the BALB/c(a)  form of IgG2a. Anti-Id  antibodies  were also obtained  in B.C8 
mice  immunized  with  purified  C.AL20,  P/J,  and  DBA/2  anti-CBPC101  antibodies 
(Table III).  The  titer of anti-Id  antibodies  obtained  in BAB. 14 and  CXBI  mice was 1338  REGULATION  OF  ANTI-ALLOTYPE  RESPONSE 
TABLE  II 
Hemagglutination of SRBC Coated with BALB/c Anti-CBPIOI  Antibody By BAB. 14 
and CXBI Anti-ld Sera 




SRBC coated with 
UPC10  MOPC 195  MOPC31  UPC61 
CXBI anti-(BALB/c  17"  3  3  2  3 
anti-CBPC 101) 
CXBI normal serum  2  0  0  0  0 
BAB. 14 anti-(BALB/c  18  2  4  3  1 
anti-CBPC 101) 
BAB. 14 anti-(BALB/c  4  4  3  4  0 
anti-Ova) 
BAB. 14 normal serum  1  0  0  0  0 
CBPC101  (10 mg/ml)  3  0  0  0  0 
C57BL/6 Ig (2 mg/ml)  0  0  0  0  0 
* HA titer (log2). 
TABLE  III 
HA Titer of Anti-ld Sera Raised in  Various Strains of Mice Immunized with Purified Anti- 
CBPC  I O  I Antibody 
Immunization with 
Strain in which 
anti-ld serum was 
raised 
Anti-Id serum adsorbed 
with 
BALB/c 
Nothing  IgG 
(3 mg/ml) 
BALB/c anti-CBPC 101 antibody*  BAB. 14  18¶  17 
CXBI  17  15 




C.AL20 anti-CBPC101 antibody:~  B.C8  6  5 
P/J anti-CBPC 101 antibody§ 
Nothing  P/J IgG 
(3 mg/ml) 
B.C8  5  3 
DBA/2 anti-CBPC101  antibodyl[ 
DBA/c 
Nothing  IgG 
(3 mg/ml) 
B.C8  5  5 
* Indicator ceils: SRBC coated with BALB/c anti-CBPC101  antibody. 
:~ Indicator cells: SRBC coated with C.AL20 anti-CBPC101  antibody. 
§ Indicator cells: SRBC coated with P/J anti-CBPCl01  antibody. 
II Indicator cells: SRBC coated with DBA/2 anti-CBPC101  antibody. 
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higher than the titer of anti-Id antibodies obtained in B.C8 mice. This may be related 
to the  heightened  immogenicity of a  complex between  IgG~  b and  anti-CBPC101 
antibody  that  can  occur  during  immunization  of BAB.14  and  CXBI  mice  with 
BALB/c anti-CBPC101  antibody, but cannot occur in B.C8(IgG~  ~) mice. 
Utilizing a radioimmunoassay  (RIA), excellent binding of 3H-BALB/c, C.AL20, 
P/J, and DBA/2 anti-CBPC101-purified antibody by BAB. 14 and B.C8 anti-Id sera 
was obtained (Fig.  1). The 8H-BALB/c anti-CBPC101  antibody was also bound by 
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9 
O~O  B.C 8 normal serum 
6  ~  BAB.14normal  serum 
BAB.14 anti RALB/C anti OVA 
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O----Q  B.CSanti BALB/Canti CBPC 101 
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Fxo.  1.  Binding ofaH-anti-CBPCl01  antibodies by BAB. 14 and B.C8 anti-ld antibodies. Micro- 
titer plates were coated with varying dilutions of anti-Id antiserum or normal serum. The capacity 
of these sensitized plates to bind aH-anti-CBPCl01  antibodies produced in BALB/c (A), C.AL20 
(B), P/J (C), and DBA/2 (D) mice is illustrated. 1340  REGULATION OF ANTI-ALLOTYPE RESPONSE 
normal BAB. 14 serum and by BAB. 14 antiserum specific for the Id of BALB/c anti- 
Ova antibody, as expected, because these sera contain IgG2a b molecules. However, the 
binding  of  3H-BALB/c  anti-allotype  antibody  to  BAB.14  anti-(BALB/c  anti- 
CBPC 101)  antibody was substantially greater than that of the control sera and could 
be observed at  a  10 -G dilution;  at such  a  dilution,  the control sera had no binding 
activity. The 3H-BALB/c anti-CBPC 101 antibodies were significantly bound by B.C8 
anti-Id serum but not by normal B.C8 serum  (Fig.  1 A). The aH-C.AL20  and DBA/ 
2 anti-CBPC 101 antibodies were not significantly bound by BAB. 14 and B.C8 normal 
sera but were strongly bound to BAB.14 and B.C8 anti-Id sera (Fig.  1 B and D). The 
3H-P/J  anti-CBPC101  antibodies were significantly bound to BAB. 14 normal serum 
diluted  10 -2. However, the binding of these labeled antibodies by BAB. 14 and B.C8 
anti-Id antisera was significantly higher than that of corresponding normal sera at all 
dilutions  (Fig.  1 C). 
These  results  indicate  that  immunization of BAB.14,  CXBI,  or  B.C8  mice  with 
purified  anti-CBPC101  allotype  antibody  led  to  the  production  of  antisera  that 
contained antibodies against Id determinants of BALB/c, C.AL20,  P/J,  and DBA/2 
anti-IgG2a b allotype  antibodies.  Preincubation  of aH-anti-CBPC101  antibody  with 
unlabeled anti-CBPC 101  or with the Fc fragment of CBPC 101  strongly inhibited the 
subsequent binding of 3H-antibody to both BAB. 14 and B.C8 anti-Id antisera coated 
on microtiter plates (Table IV). This result indicates that the binding of Id by anti-Id 
is  inhibited  in  the  presence of antigen  (IgGz~)  and  thus suggests  that  the  idiotypic 
determinants of the anti-allotype antibodies are associated with the antigen combining 
site. 
Presence  of  IdX  on  Anti-(IgG2ab)-Allotype  Antibodies  Produced  by  Various  individual 
BALB/c  Mice  and by  Mouse  Strains  of the  b,  d,  p,  q,  r,  and s  MHC  Haplotypes.  Anti- 
allotype  sera  from  nine  individual  BALB/c  mice  were  used  to  inhibit  subsequent 
TABLE IV 
Inhibition of Binding ofaH-Anti-CBPClO1 Antibody to B.C8 and BAB. 14 Anti-Id Sera by Fc Fragments 
of CBPC I O  I Myeloma Protein 
Inhibitors 
Percent  inhibition of binding in radioimmunoassay 
Plates coated  with B.C8 anti-ld serum 
Plates coated  with BAB. 14 anti-(BALB/c  anti- 
CBPCIOI) 
all-  :~H-  3H-  :~H- 
all-  all-P/J§  :~H-  *H-P/J 
BALB/c* C.AL20~  anti-  "anti-  DBA/2]I  BALB/c  C.AL20 anti-  anti-  DBA/2 
anti-  anti-  anti-  anti- 
CBPCI01  an- CBPCI01  CBPCI01  an- CBPCI01 
CBPC 101  CBPC 101  CBPC 101  CBPC 101 
tibody  antibody  tibody  antibody 
antibody  antibody  antibody  antibody 
BALB/c  anti-CBPC 101 
(1  mg/rnl) 
C.AL20 anti-CBPC 101 
(1.3  mg/ml) 
P/J anti-CBPC 101 
(1  mg/rnl) 
DBA/2 anti-CBPC 10 I 
(0.4 mg/ml) 
Fc fragment of CBPC 101 
(75 ,ug/ml) 
UPC 10 (10 mg/ml) 
97  --  -- 
--  85 
--  --  89  -- 
--  52 
98  95  97  96 
3  5  18  4 
96 
--  95 
--  --  93  -- 
--  --  81 
98  88  95  94 
2  I1  6  4 
* Plates coated  with B.C8 anti-(BALB/c  anti-CBPCl01). 
Plates coated  with B.C8 anti-(C.AL20 anti-CBPCl01). 
§ Plates coated  with B.C8 anti-(P/J anti-CBPCI01). 
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binding  of  anti-Id  antibody  in  HA  and  RIA  tests  to  determine  whether  the  Id 
expressed on  the anti-allotype antibodies of the individual BALB/c  mouse  used  to 
produce BAB. 14 and CXBI anti-Id antibodies was also expressed on the anti-allotype 
antibodies of other BALB/c mice. As can be seen in Table V, all nine BALB/c mice 
produced a  high titer of anti-allotype antibodies. Sera of each of these mice inhibited 
binding of CXBI  anti-Id antisera in both  HA and  RIA tests. With BAB.14 anti-Id 
serum,  six  of the  nine  individuals  showed  a  substantial  inhibitory  titer  in  RIA, 
although less than they had exhibited with the CXBI anti-Id antibody. These results 
suggest that idiotypic determinants were shared by anti-allotype antibodies produced 
in various individual BALB/c mice. 
Anti-CBPC101  antisera  from  12  responder  strains  of mice  were  tested  for  the 
presence of IdX by determining their ability to inhibit the reaction between B.C8 and 
BAB. 14 anti-Id sera and SRBC that were coated with BALB/c anti-CBPC 101  (Table 
VI).  Anti-allotype antisera  from  each  of these  strains  inhibited  hemagglutination 
indicating the sharing of IdX by their anti-allotype antibodies. Similar results were 
obtained by RIA using 3H-BALB/c  anti-CBPC101  antibodies and  BAB.14  anti-Id 
antiserm. 
In general, mice of the H-2 b type developed lower IdX HI titers than did mice of 
other responder MHC  types. The expression of IdX on  anti-allotype antibody was 
observed in mice of each 1gh-C type tested; this included the a, c, g, h, and o types. We 
could not determine the capacity of mice of the b lgh-C type to produce IdX because 
these  mice  possess  IgG~  b  and  thus  do  not  produce  anti-allotype antibodies  upon 
immunization with CBPC101. 
The IdX was not expressed on a  goat anti-IgG2a  b anti-allotype antibody which was 
raised  by  immunization  with  the  Fc  fragment  of CBPCI01.  Similarly, sera which 
were principally specific for idiotypic determinants of CBPC 101  raised in responder 
TABLE  g 




HA titer (logz); SRBC coated  HI titer (log2)*  with 
CBPC101  C57BL/6-Ig  UPCI0 
Inhibition of RIA$ 
BAB.14  CXBI  BAB.14  CXBI 
anti-Id  anti-Id  anti-Id  anti-Id 
serum  serum  serum  serum 
1  >12  >12  0  4  8  3  1,000 
2  >12  >12  0  8  >8  100  1,000 
3  >12  >12  0  8  >8  100  1,000 
4  >12  >12  0  >8  >8  100  1,000 
5  >12  >12  0  7  >8  30  1,000 
6  >12  >12  0  3  >8  100  1,000 
7  >12  >12  0  2  >8  <10  100 
8  >12  >12  0  2  >8  <10  1,000 
9  >12  >12  0  7  >8  30  1,000 
* SRBC were coated with specifidally purified BALB/c anti-CBPC 101 antibodies. 
$ Plates were coated with a 1:50,00 dilution of either BAB.14 or CXBI anti-(BALB/c anti-CBPCl01)  and 
incubated with the following dilutions  of anti-CBPCl01 antisera from individual BALB/c mice:  1:3, 
1:10, 1:30, 1:100, 1:300, and 1:1,000. The capacity of aH-BALB/c anti-CBPC 101 antibodies to bind to 
the plate was then tested. Results are expressed as l/highest dilution of serum causing >50% inhibition 
of binding. 1342  REGULATION OF ANTI-ALLOTYPE RESPONSE 
TABLE VI 
Expression of ldX on Anti-Allotypes  Antibodies Produced in  Various Stratus of Mice 
Strain Immu-  MHC  Igh-C 
nized  type  type 
HI: SRBC coated  Inhibition of bind- 
with BALB/c anti-  ing of 3H-BALB/c 
CBPCI01; anti-ld  anti-CBPC101  by 
produced in  BAB. 14 anti- 
(BALB/c anti- 
B.C8  BAB. 14  CBPC101) 
BALB/c  d  a  >8"  >8  1,000~ 
BALB.B  b  a  3  6  10 
B.C8  b  a  2  3  5 
CXBG  b  a  4  6  30 
CXBJ  b  a  3  4  3 
129/SV  b  a  3  4  100 
DBA/2  d  c  6  >8  1,000 
DBA/1  q  c  >8  5  100 
C.AL20  d  o  7  >8  1,000 
RIII  r  g  6  >8  650 
P/J  p  h  2  >8  650 
SJA  s  a  >8  >8  1,000 
* l/log2 of the highest dilution causing inhibition of hemagglutination. 
:~ Microtiter plates were coated with a  1:50,000 dilution of BAB. 14 anti-(BALB/c anti-CBPC 101) 
antiserum and incubated with 1:3, 1:10, 1:30, 1:100, 1:300, 1:1,000, and 1:3,000 dilutions of anti- 
allotype serum from various strains. In some experiments, other dilutions of inhibitors were used. 
3H-BALB/c anti-CBPC101 was used for binding. The result reported is l/highest dilution ofanti- 
allotype serum causing >50% inhibition of binding. 
strains (e.g.,  129,  CXBJ,  BALB.B, and DBA/1)  and in nonresponder strains lacked 
the IdX as tested by HA assay and by RIA. 
Through the kindness of Dr. Vernon Oi, Dr. Leonard Herzenberg, and Dr. Melvin 
Bosma, we had the opportunity to study the expression of IdX on monoclonal anti- 
IgG2a  b anti-allotype antibodies obtained from  fusion of lymphocytes of BALB/c or 
SJA mice immunized with CBPC101.  Each of these hybridoma products is specific 
for allotypic determinants of CBPC101. In four cases, more precise specificity assign- 
ments have been made. Both IG(lb)5.7.1 and Ig(lb)3.1 appear to identify CH3 domain 
determinants, whereas  Ig(lb)2.9  has  been  assigned  a  CH2  domain  specificity  and 
Ig(lb)4.7, a  hinge-region specificity (13). Each of the hybridoma antibodies, with the 
exception of Ig(lb)4.7, expressed a substantial HA titer for CBPC 101  and C57BL/6- 
Ig-coated SRBC  (Table VII). All of the HA-positive hybridoma antibodies inhibited 
the binding  of BAB. 14 anti-Id sera to anti-CBPC 101 antibody, although the inhibitory 
titer depended both on the hybridoma and the strain of origin of the anti-allotype 
antibody (Table VIII). Furthermore, the two hybridomas specific for the Cna domain 
and the one reagent specific for the CH2 domain of IgGza  b each inhibited, at a dilution 
of  1:30,  >85%  of  the  binding BAB. 14  anti-Id sera  to  3H-purified  BALB/c  anti- 
CBPC 101  antibody, indicating extensive idiotypic sharing between these hybridoma 
products despite their distinctive specificities. 
Overall, these data showed that an IdX or a  family of IdX expressed by an anti- 
I  b  ....  ( gGz, )-allotype antibody originating from one individual BALB/c mouse or pools of 
C.AL20,  P/J,  and  DBA/2  anti-allotype sera  are  also  expressed  on  anti-allotype 
antibodies of various BALB/c individuals. Furthermore, this IdX was found on anti- 
allotype antibodies produced  in  various strains of mice  as  well  as  on  products  of C.  BONA, P.  K.  A.  MONGINI,  K.  E.  STEIN,  AND W.  E.  PAUL 
TABLE VII 
Properties of Hybridoma Anti-IgG2~ b Allotype Antibody 
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Hybridoma 
Specificity  Specificity  Ig class of  HA titer (log2) 
Immunized  of 
for Fc  hybridoma  CBPCI01  C57BL/6  donors  hybridoma  domains  product 
product  SRBC  Ig SRBC 
10-3.6  CW.B  IA. 17  --  G2a  0  0 
Ig(lb) 5.7.1  BALB/c  IgG  b  CH3  G3  12  >12 
Ig(lb)3.1  BALB/e  IgG b  CH3  G 1  11  l0 
Ig(1  b) 2.9  BALB/e  IgG  b  CH2  G2a  12  > 12 
Ig(lb)4.7  SJA  IgG2a  b  Hinge  G 1  0  0 
S IG. IE  BALB/e  IgG2a  b  ND*  G 1  24  24 
S IA. 1A  BALB/c  IgG  b  ND  G 1  24  24 
BALB/c anti-  BALB/c  IgG  2a b  ND  ND  12  16 
CBPC 101 
antibody 
* ND, not done. 
TABLE VIII 




HI titer (log2); SRBC coated with  Inhibition  of RIA using all-labeled 
BALB/c*  C.AL20*  P/J*  DBA/2*  BALB/c*  C.AL20*  P/J*  DBA/2* 
Ig(lb)5.7.1  >8  >8  5  4  100~:  1,000  10  10 
Ig(lb)3.1  5  ND§  ND  ND  100  ND  ND  ND 
Ig(lb) 2.9  4  2  2  >8  >300  10  10  30 
Ig(lb)4.7  0  ND  ND  ND  <3  ND  ND  ND 
S1G.1E  2  >8  2  >8  3  100  <10  30 
S1A.1A  2  >8  4  >8  10  30  <10  100 
10-3.6  0  0  0  0  <3  ND  ND  ND 
* Anti-CBPCI01 antibody. 
~: Results are reported as 1/greatest dilution of hybridoma product which gave >50% inhibition of binding 
of SH-anti-allotype antibody to plates coated with a  1:50,000 dilution of BAB.  14 anti-(BALB/c anti- 
CBPC 101) antiserum. Dilutions tested were 1:3, 1  : 10, 1:30, 1  : 100, 1:300, 1  : 1,000, and 1:3,000. 
§ ND, not done. 
hybridomas. The  relatedness of the  anti-allotype antibodies was  further  tested  by 
studying  the  ability  of  anti-Id  sera  produced  in  BAB.14,  CXBI,  and  B.C8  to 
agglutinate SRBC  that were coated with BALB/c, C.AL20,  P/J,  and DBA/2 anti- 
CBPC101-purified antibody. The  results presented  in Table IX  show  that  anti-Id 
antibodies raised against BALB/c, BALB.B, DBA/2, P/J, and C.AL20 anti-CBPC 101 
antibodies each  interacted, with  two  exceptions, with  BALB/c,  DBA/2,  P/J,  and 
C.AL20 anti-IgG2a  b allotype antibodies. These observations provide further support 
for the conclusion that  anti-IgG2a  b antibodies produced in various strains express a 
substantial degree of idiotypic similarity. 
Isoelectric Focusing Pattern of Anti-Allotype  Antibodies.  Anti-CBPC101 antibodies pro- 
duced by a  variety of responding strains showed strikingly similar isoelectric focusing 
patterns when tested for their ability to bind 125I-Fc fragments of CBPC 101 myeloma 
protein (Fig. 2). The anti-CBPC 101 sera of some strains (B.C8,  129, and DBA/2) did 
differ from other strains in that they lacked antibodies which focused in basic regions 
of the gel. However, the Fc CBPC101-binding antibodies found in these strains were 1344  REGULATION OF  ANTI-ALLOTYPE  RESPONSE 
TABLE  IX 
Expression of ldX on BALB/c, C.AL20, P/J, and DBA/2 Anti-Allotype (IgGea  b) 
Antibody 
Strain in which 
anti-Id antise-  Immunogen: 
anti-CBPC 101 
rum was pro-  produced in 
duced 
HA titer (log2); SRBC coated with 
BALB/c*  C.AL20*  P/J*  DBA/2* 
BAB. 14  BALB/c  8  >8  >8  >8 
CXBI  BALB/c  8  >8  >8  >8 
B.C8  BALB/c  7  6  6  6 
B.C8  BALB.B  7  6  8  8 
B.C8  C.AL20  6  6  6  1 
B.C8  P/J  5  0  5  5 
B.C8  DBA/2  6  6  6  8 
* Anti-CBPC101  antibody. 
shared with other responding strains. As anticipated, sera from nonresponder strains 
(C58 and [BALB/c ×  C57BL/6]F1) failed to bind Fc CBPC101. 
Discussion 
The results reported here indicate that the capacity of mice to produce antibodies 
specific for allotypic determinants of the IgG2a  b type is associated with the MHC of 
the responding individuals, with strains of the b, d, p, q, r, and s MHC  types being 
responders. The best evidence for the role of MHC genes in controlling this response 
is provided by the distinctive response patterns of BALB/c congenic mice;  indeed, 
BALB/c and  BALB.B mice respond  to CBPC101,  whereas  BALB.K mice do not. 
This demonstration of MHC-gene control of responses to the |gGza  b allotype provides 
the third example of Ir gene control of anti-immunoglobulin responses (8, 9). 
Mice  of each  of the  responder MHC  haplotypes  make  anti-allotype  antibodies 
which express IdX determinants found on BALB/c, C.AL20, P/J, and DBA/2 anti- 
CBPC 101 antibodies and identified by BAB. 14, CXBI, and B.C8 anti-Id antibodies. 
Study  of these  antibodies  by  isoelectric  focusing  indicates  that  the  anti-allotype 
antibody response is of limited heterogeneity. 
The expression of an IdX by anti-immunoglobulin antibodies extends the obser- 
vations of Kunkel et al.  (14)  that  monoclonal human  IgM proteins specific for IgG 
share an IdX and that  the light  (L) chains of these proteins demonstrate a  striking 
restriction of Ig L-chain variable region (Igl-V) subgroup (15). 
The IdX identified on anti-CBPC101  antibodies are expressed on five of six anti- 
IgG2a  b hybridoma products. These IdX  + hybridomas are of the IgGl, IgGz~, and IgGa 
classes,  indicating that the expression of the IdX is not limited to Ig of a single class. 
Furthermore, of the IdX  + hybridomas, two are specific for a Cna-domain determinant 
and one for a  CH2 determinant  (13).  This demonstration that  IdX are expressed on 
antibodies of apparently  different specificities has clear precedence in  the  work of 
Oudin and Cazenave on expression of idiotypic determinants on antibodies to distinct 
fragments of fibrinogen (16)  and on sharing of Id by anti-Ova antibodies and by Ig 
that lacks Ova specificity (17). Similarly, Eichmann et al. (18) have reported that the 
A5A idiotype is expressed on both anti-streptococcus A carbohydrate antibody and 
on Ig molecules that are not specific for such determinants. It is a provocative finding C.  BONA,  P.  K.  A.  MONGINI, K.  E.  STEIN, AND W.  E.  PAUL  1345 
FIo.  2.  Isoelectric  focusing  patterns  of anti-CBPCl01  antibodies produced  by various strains  of 
mice.  10 #1 of antiserum (B.CS, (2XBJ, CXBG, C.AL20, [BALB/c ×  C57BL/6]F~,  and C58/J), of 
a  1:4 dilution of antiserum in normal BALB/c serum  (DBA/2 and  P/J), or of a  1:8 dilution of 
antiserum in normal BALB/c serum (RIII and  129) were focused. Gels were overlaid with a  l~l- 
labeled Fc fragment of CBPCI01. Radioautographs were exposed  for 7 d before development. 
that  in  our  studies  and  that  of Cazenave  and  Oudin  (16),  antibodies  to  distinct 
determinants  on  the  same  molecule  share  idiotypic  determinants.  The  observation 
that  the  IdX  of the  anti-IgGz,  b  antibodies  are  associated  with  the  combining  site 
reinforces the interest of this finding.  Possible explanations  for such  idiotypic sharing 
by  antibodies  recognizing  distinct  specificities  on  the  same  molecule  is  that  the  V- 1346  REGULATION  OF  ANTI-ALLOTYPE  RESPONSE 
region gene for one antibody arose by somatic mutation from the gene for the other 
(or from a common precursor) and that the presence of antigen selectively stimulated 
the  mutant  clone.  Alternatively, T  lymphocytes or  antibody specific for the  IdX, 
generated in response to one determinant on the molecule, may have been indirectly 
focused upon  B  lymphocytes specific for other determinants on  the same  molecule 
and thus favored the stimulation of IdX + clones specific for any determinant on the 
antigen used for immunization. 
The expression of IdX on anti-allotype antibodies has been  found in  mice of all 
Igh-C types thus far studied, with the exception of the b type. The latter, of course, 
fails to produce anti-IgG2a  b antibody under normal conditions. This sharing of IdX 
among antibodies of a  variety of Igh-C types has previously been noted in the Id of 
anti-phosphocholine (19), anti-(Glu,Ala,Tyr) (20), and anti-galactan antibodies (21). 
Recently, anti-Km(1) cryoglobulins in several members of a human family expressed 
an IdX, the appearance of which was linked neither to their Gm type nor their HLA 
3  type. 
The finding of the similarity in anti-IgGza  b anti-allotype antibodies among a wide 
variety of strains  suggests  that  the  capacity  to produce such  antibody  is  a  highly 
conserved function, perhaps reflecting the existence of a germ-line Ig H-chain-variable 
region (Igh-V) gene or family of closely related genes. One may ask why the capacity 
to produce anti-allotype antibodies should be of sufficient evolutionary significance so 
that  this  ability  would  exhibit  the  degree  of conservation  noted.  One  obvious 
possibility is that the Igh-V genes that encode the combining portion of the H  chain 
may also code for important molecules that normally regulate the expression of given 
Ig classes. That is, such Igh- V genes may code for T  cell recognition molecules which, 
in mice of IgG2a  b type, regulate the expression of B cells capable of producing IgG2~. 
In a similar vein, Bellgrau and Wilson (22) have recently reported that  (A X B)F1 
rats  immunized against  T  cells  from  an  A  donor are  resistant  to  graft-versus-host 
responses mounted by T  cells from A donors and from (A X C), (A x  D) ... (A X N) 
F1 donors. They interpret these results as indicating that there is a  limited polymor- 
phism  of idiotypic determinants on T  cell receptors specific for MHC  alloantigens 
and  that  the  (A  X  B)F1  has made a  response against  idiotypic determinants on  A 
receptors specific for B  MHC  antigens.  Furthermore, the  finding that  graft-versus- 
host reaction resistance extends to cells of a series of other MHC types reacting against 
B antigens suggests that receptors of A, C, D... N  rats specific for B MHC antigens 
share Id.  The obvious role of MHC  gene products as targets  for self-recognition in 
normal  immune  responses  may  suggest  conservation  of  responsiveness  to  MHC 
antigens, because such responsiveness is critical to the normal function of the immune 
system. In  that  respect, one might  attempt  to draw strong parallels between MHC 
recognition in cellular interactions and Ig recognition in regulation of class, allotype, 
and Id of antibody. 
Summary 
The anti-allotype antibody response to the b allotypic form of IgGza is regulated by 
major histocompatibility complex (MHC)-encoded immune response (It) genes. Mice 
of d, b, p, q, r, and s haplotypes make a strong anti-allotype response on immunization 
a Nightingale, S, D., W. B. Bias, N. L. Delancy, and R. P. Pelley. Manuscript submitted for publication. C.  BONA, P.  K. A.  MONGINI, K. E. STEIN, AND W.  E.  PAUL  1347 
with the CBPC101  myeloma protein  (IgG~b), whereas mice of the k, m, a, 01, u, and 
z haplotypes made no, or a  very poor, response. 
All responder strains produce anti-IgG~  b antibodies which share common idiotypes 
(Id) without relation to the allelic forms of the Ig heavy-chain-constant region genes 
that  the  responding  mice  possess.  Isoelectric  focusing  analysis  of the  anti-allotype 
antibodies  produced  in  various  strains  of  mice  showed  that  they  are  of limited 
heterogeneity  and  quite  similar  from  strain  to  strain.  Five  out  of six  hybridoma 
products  with  specificity  for  CBPC101  allotype  expressed  cross-reactive  idiotypes 
(IdX). Two ofhybridoma products expressing IdX identify Can-domain determinants, 
and one has been assigned a Cm-domain specificity. 
We wish  to express  our thanks  to  Ms.  Rose  Lieberman  for many helpful  discussions  and 
suggestions. 
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